Sign in
Active, not recruitingPhase 3

Efficacy and Safety of ELIXCYTE Intra-articular Injection in Subject With Knee Osteoarthritis

Key facts

Who runs it
UnicoCell Biomed CO. LTD
Where
Taiwan4 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 3
People taking part
165 people, planned
Started
3 Jul 2023
Expected to end
Nov 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • ELIXCYTE
  • Saline
Record updated
21 November 2025

Who can take part

Age
40 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 40 criteriaShow less

Who can take part

  • A subject is eligible for the study if all of the following apply:
  • Either gender, aged 40 to 80
  • With unilateral/bilateral knee OA of Kellgren-Lawrence grading II-III (determined by American College of Rheumatology criteria of knee OA)
  • WOMAC pain score of 7 - 17 in the target knee even if treated with chronic doses of NSAID
  • Has received 1 - 3 types of pharmacological therapies for knee OA for more than 3 months but the symptoms have not relieved
  • Unwilling or not suitable to undergo knee surgery (including total knee replacement and knee arthroplasty)
  • Understands and has signed the informed consent form
  • With adequate hematological indices:; White blood cell (WBC) ≥ 3,000/mm3; Platelet count ≥ 80,000/μL
  • With adequate coagulation indices: Prothrombin time (PT), international normalized ratio (INR), and activated partial thromboplastin time (APTT) ≤ 1.5 times the upper limit of the normal range (ULN)
  • With adequate liver function where serum total bilirubin ≤ 1.5 times ULN, aspartate aminotransferase (AST) ≤ 3 times ULN, and alanine aminotransferase (ALT) ≤ 3 times ULN
  • Has an estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m2, calculated by the Modification of Diet in Renal Disease (MDRD) equation

Who cannot take part

  • With previous surgery of articular fracture, ligament reconstruction, meniscal reconstruction (with the exception of meniscal debridement), and knee arthroplasty on the target knee joint
  • Administered systemic immunosuppressive agent, systemic antiinflammatory drug, systemic steroid, systemic analgesics (except acetaminophen, and tramadol as rescue medications), duloxetine, or over-the-counter medications contain analgesics (e.g. cold medicine) within 2 weeks prior to screening. Administered systemic herbal, homeopathic, or naturopathic remedies for knee OA within 2 weeks prior to screening. A subject requiring routine use of low-dose Aspirin for preventing thrombosis (≤ 100 mg/day) will not be excluded from this study
  • Administered local immunosuppressive agent, local anti-inflammatory drug, local steroid, local analgesics, over-the-counter medications contain analgesics, herbal, homeopathic, or naturopathic remedies for knee OA within 2 weeks prior to screening
  • Has participated in other investigational studies within 4 weeks prior to screening
  • Administered monoamine oxidase inhibitor, selective serotonin reuptake inhibitor, serotonin-norepinephrine reuptake inhibitors, benzodiazepine, or tricyclic antidepressants within 4 weeks prior to screening
  • Known or suspected hypersensitivity to any ingredients of the investigational product (ELIXCYTE) or contrast medium for magnetic resonance imaging (MRI)
  • With joint diseases expect knee OA that is considered not eligible to enter the study by the investigator
  • Systemic diseases that may affect joints, including but not limited to inflammatory joint diseases, reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and fibromyalgia
  • Known or suspected infection around the target knee joint
  • With any evidence of malignant disease with a life expectancy less than 1 year
  • With a known history of human immunodeficiency virus (HIV) infection
  • With a known history of alcohol abuse
  • With a known history of opioid dependent
  • Has any existing active/inactive implanted medical devices that pose a safety risk during MRI examination, such as a cardiac pacemaker, cochlear, intracranial vascular clips, or neurostimulator, etc
  • Known allergy to acetaminophen and tramadol
  • Has any abnormal radiographic evidence of target knee, such as excessive malalignment, other arthropathies, or systemic metabolic bone disease, etc
  • Known any contraindication to IA intervention of the target knee, such as skin infection of injection site, coagulopathy, or routine use of anticoagulant, etc; For exclusion criteria #21 and #22, acceptable forms of birth control include:
  • With any IA intervention of the target knee within 3 months prior to screening (e.g. steroid, anesthetic), or sodium hyaluronate by IA intervention of the target knee within 6 months prior to screening
  • Has serious medical conditions or ongoing disease (e.g. concomitant illness such as cardiovascular (e.g. New York Heart Association grade III or IV), hepatic (e.g. Child-Pugh Class C), psychiatric condition, alcoholism, drug abuse), medical history, physical findings, or laboratory abnormality that in the investigators' opinion could interfere with the results of the trial or adversely affect the safety of the subject
  • Any subject meeting any of the exclusion criteria will be excluded from study participation
  • Body mass index (BMI) ≥ 35 kg/m2
  • Judged to be not applicable to this study by investigator such as the difficulty of follow-up observation
  • Has claustrophobia and/or cannot take MRI test
  • Has any existing metallic intraocular foreign body that pose a safety risk during MRI examination
  • Female subject of childbearing potential who:; Is lactating; or; Has positive pregnancy test result at eligibility checking; or; Refuses to adopt at least one form of birth control from signing informed consent to the end of the study
  • Male subject with female spouse/partner who is of childbearing potential refuses to adopt at least one form of birth control from signing informed consent to the end of the study
  • Established use of oral, injected, or implanted hormonal methods of contraception
  • Placement of an intrauterine device (IUD) or intrauterine system (IUS)
  • Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps)

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a Phase III, double-blinded, placebo-controlled, multicenter study to investigate the efficacy and safety of a new study intervention, ELIXCYTE, compared to placebo (normal saline) in subjects with knee osteoarthritis. The primary hypothesis of the study is to demonstrate that ELIXCYTE is superior to placebo (saline) in improving knee pain on the target knee from baseline.

Read full original descriptionShow less

During the study, each participant will receive either ELIXCYTE (study intervention) or placebo (normal saline) intra-articular injection once on the target knee after eligibility criteria check. The target knee will be assessed by X-ray, MRI and subject self-evaluation knee questionnaires (WOMAC, KSS and KOOS) in the following visits. Other safety assessments, including lab test, physical examination, vital sign, medical/medication history and adverse events will also be collected throughout the study.

The 2 groups in the trial

  • ELIXCYTETreatment being tested

    Subjects will be intra-articular (IA) injected with 4 mL of ELIXCYTE (containing 32×10\^6 ADSCs) at the target knee once

  • Placebo control (Saline)Placebo, for comparison

    Subjects will be intra-articular (IA) injected with 4 mL of saline at the target knee once

    Treatment: Saline

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase III, Randomized, Parallel, Double-blinding, 2-Arm Study to Investigate the Efficacy and Safety of Intra-articular ELIXCYTE (Adipose-Derived Stem Cells) Injection Compared With Placebo in Subjects With Knee Osteoarthritis
Record updated
21 November 2025